Greenwich Wealth Management LLC lifted its stake in Annovis Bio, Inc. (NYSE:ANVS – Free Report) by 19.9% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 15,075 shares of the company’s stock after purchasing an additional 2,500 shares during the quarter. Greenwich Wealth Management LLC owned 0.13% of Annovis Bio worth $87,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. Cetera Advisors LLC acquired a new position in shares of Annovis Bio in the 1st quarter valued at $122,000. Redmond Asset Management LLC boosted its position in shares of Annovis Bio by 6.1% in the 1st quarter. Redmond Asset Management LLC now owns 36,157 shares of the company’s stock valued at $430,000 after purchasing an additional 2,077 shares during the period. Finally, Vanguard Group Inc. boosted its position in shares of Annovis Bio by 6.1% in the 1st quarter. Vanguard Group Inc. now owns 357,942 shares of the company’s stock valued at $4,260,000 after purchasing an additional 20,588 shares during the period. Institutional investors and hedge funds own 15.83% of the company’s stock.
Annovis Bio Price Performance
ANVS opened at $8.02 on Tuesday. Annovis Bio, Inc. has a fifty-two week low of $4.53 and a fifty-two week high of $22.49. The business has a 50-day moving average of $9.53 and a 200-day moving average of $8.94. The company has a market capitalization of $89.59 million, a PE ratio of -1.39 and a beta of 1.73.
Analyst Ratings Changes
Several equities research analysts recently issued reports on the company. EF Hutton Acquisition Co. I raised Annovis Bio to a “strong-buy” rating in a research note on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $30.00 price objective on shares of Annovis Bio in a research note on Thursday, August 15th. Finally, Rodman & Renshaw reissued a “buy” rating and issued a $67.00 price objective on shares of Annovis Bio in a research note on Tuesday, July 2nd. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $33.60.
View Our Latest Research Report on ANVS
Annovis Bio Profile
Annovis Bio, Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases.
Featured Articles
- Five stocks we like better than Annovis Bio
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Palo Alto Analysts Drive it to New Highs: 50% Upside Is Possible
- Using the MarketBeat Dividend Yield Calculator
- Roblox’s Growth Beyond Kids: Stock Set for Major Moves
- How to Read Stock Charts for Beginners
- 5 Oversold Stocks to Buy Right Now
Receive News & Ratings for Annovis Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Annovis Bio and related companies with MarketBeat.com's FREE daily email newsletter.